SMAD4 and synovial sarcoma: In conclusion, we have shown that disruption of the Smad4 pathway in T cells of NOD mice dysregulates effector T cell activation not by an alteration of Treg function, but by upregulation of Th17, which may contribute to the acceleration and increase of the development of the SS-like symptoms in NOD mice.